Top

Published in:

29-03-2022 | Metastasis | Case report

Conversion surgery for initially unresectable advanced biliary tract cancer treated with gemcitabine plus cisplatin combination chemotherapy: a case report and literature review

Authors: Ryoichi Miyamoto, Toshiro Ogura, Amane Takahashi, Hiroyuki Ishida, Shinichi Matsudaira, Katsumi Amikura, Yuko Suzuki, Satoshi Shimizu, Atsushi Kihara, Hiroaki Kanda, Yoshiyuki Kawashima

Published in: International Cancer Conference Journal | Issue 3/2022

Abstract

Recently, the number of reports describing patients with initially unresectable biliary tract cancer (BTC) who underwent resection in the form of conversion surgery is increasing. Gemcitabine plus cisplatin (GC) combination therapy has been reported to significantly prolong the median survival time from 8.1 to 11.7 months compared with conventional gemcitabine therapy in patients with unresectable BTC. We report the case of a patient with unresectable BTC who underwent conversion surgery with a partial response to GC combination therapy. A 78-year-old woman was diagnosed with unresectable BTC with invasion of the right hepatic artery by lymph node metastasis and liver metastases. The patient received GC combination therapy. After 6 cycles of chemotherapy, the patient achieved a partial response. The radiological findings revealed a marked shrinkage in the primary lesion and the disappearance of lymph node and liver metastases. Therefore, the patient underwent conversion surgery, including biliary tract resection and regional lymph node dissection. For postoperative follow-up, the patient was monitored without receiving adjuvant chemotherapy. The patient had not exhibited recurrence during the 12-month follow-up period. We report the case of a patient with unresectable BTC who underwent conversion surgery with a partial response to GC combination therapy.

Randi G, Malvezzi M, Levi F et al (2009) Epidemiology of biliary tract cancers: an update. Ann Oncol 20:146–159CrossRef

Hori M, Matsuda T, Shibata A et al (2015) Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 45:884–891CrossRef

Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281CrossRef

Morizane C, Okusaka T, Mizusawa J et al (2019) Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol 30:1950–1958CrossRef

Sakai D, Kanai M, Kobayashi S et al (2018) Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). Ann Oncol 29:viii205–viii270CrossRef

Kato A, Shimizu H, Ohtsuka M et al (2013) Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol 20:318–324CrossRef

Kato A, Shimizu H, Ohtsuka M et al (2015) Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol 22:S1093–S1099CrossRef

Evans DB, Rich TA, Byrd DR et al (1992) Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127:1335–1339CrossRef

Satoi S, Yamaue H, Kato K et al (2013) Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 20:590–600CrossRef

10.

Adam R, Wicherts DA, de Haas RJ et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27:1829–1835CrossRef

11.

Bismuth H, Adam R, Levi F et al (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509–520CrossRef

12.

Rayar M, Sulpice L, Edeline J et al (2015) Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. Ann Surg Oncol 22:3102–3108CrossRef

13.

Agrawal S, Mohan L, Mourya C et al (2016) Radiological downstaging with neoadjuvant therapy in unresectable gall bladder cancer cases. Asian Pac J Cancer Prev 17:2137–2140CrossRef

14.

Engineer R, Goel M, Chopra S et al (2016) Neoadjuvant chemoradiation followed by surgery for locally advanced gallbladder cancers: a new paradigm. Ann Surg Oncol 23:3009–3015CrossRef

15.

Konstantinidis IT, Groot Koerkamp B, Do RK et al (2016) Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer 122:758–765CrossRef

16.

Creasy JM, Goldman DA, Dudeja V et al (2016) Systemic chemotherapy combined with resection for locally advanced gallbladder carcinoma: surgical and survival outcomes. J Am Coll Surg 224:906–916CrossRef

17.

Sumiyoshi T, Shima Y, Okabayashi T et al (2018) Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma. World J Surg 42:2910–2918CrossRef

18.

Le Roy B, Gelli M, Pittau G et al (2018) Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg 105:839–847CrossRef

19.

Suzuki Y, Kan M, Kimura G et al (2019) Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy. J Gastroenterol 54:281–290CrossRef

20.

Noji T, Nagayama M, Imai K et al (2020) Conversion surgery for initially unresectable biliary malignancies: a multicenter retrospective cohort study. Surg Today 50:1409–1417CrossRef

21.

Kobayashi S, Ueno M, Ohkawa S et al (2012) A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer. Jpn J Clin Oncol 42:800–806CrossRef

22.

Robinson K, Lambiase L, Li J et al (2003) Fatal cholestatic liver failure associated with gemcitabine therapy. Dig Dis Sci 48:1804–1808CrossRef

23.

Primrose JN, Fox RP, Palmer DH et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20:663–673CrossRef

24.

Nakachi K, Konishi M, Ikeda M et al (2018) A randomized Phase III trial of adjuvant S-1 therapy vs observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT). Jpn J Clin Oncol. https://doi.org/10.1093/jjco/hyy004CrossRefPubMed

Title: Conversion surgery for initially unresectable advanced biliary tract cancer treated with gemcitabine plus cisplatin combination chemotherapy: a case report and literature review
Authors: Ryoichi Miyamoto
Toshiro Ogura
Amane Takahashi
Hiroyuki Ishida
Shinichi Matsudaira
Katsumi Amikura
Yuko Suzuki
Satoshi Shimizu
Atsushi Kihara
Hiroaki Kanda
Yoshiyuki Kawashima
Publication date: 29-03-2022
Publisher: Springer Nature Singapore
Keywords: Metastasis
Cholangiocarcinoma
Cholangiocarcinoma
Cytostatic Therapy
Published in: International Cancer Conference Journal / Issue 3/2022
Electronic ISSN: 2192-3183
DOI: https://doi.org/10.1007/s13691-022-00545-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2022

Two cases showing the effects of bevacizumab on recurrent cervical cancer with pleural effusion

Well-differentiated liposarcoma causing non-islet cell tumor hypoglycemia

Liver metastasis 13 years after the resection of a malignant triton tumor originating in the duodenum

Detection of relatively poor but definitive blood supply in prostate stromal sarcoma using transrectal ultrasonography with superb microvascular imaging

Focal xanthogranulomatous inflammation of the kidney cyst without pyelitis: a rare presentation mimicking kidney cancer

Gastric carcinoma with lymphoid stroma derived from hamartomatous inverted polyp with osteoclast-like giant cells: a case report

Keynote webinar | Spotlight on antibody–drug conjugates in cancer